BIOCON LTD.

Biocon Ltd issued a reminder to shareholders who have not claimed their dividends for seven consecutive years, specifically from the financial year 2018-19 onwards. The notice urges shareholders to claim their dividends by August 20, 2026, to avoid the transfer of both the unclaimed dividends and the corresponding shares to the Investor Education and Protection Fund (IEPF). The company has provided details of unclaimed dividends on its website and through reminder letters.

Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from Health Canada for its micafungin for injection, USP, in 50 mg and 100 mg dosages. The product is approved for treating Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem cell transplantation patients. This approval is expected to strengthen Biocon's portfolio of biosimilars and generics.

Biocon Ltd's board reviewed the Monitoring Agency Report by India Ratings & Research for the quarter ended March 31, 2026, regarding the utilization of proceeds from Qualified Institutions Placements (QIP). The report indicates no deviation from the stated objectives. This review complies with SEBI regulations and is available on the company's website.

Biocon Ltd clarified a news report suggesting Kiran Mazumdar-Shaw's succession, stating that she continues to serve as the Executive Chairperson. The company confirmed there are no impending changes in executive management or ownership succession requiring disclosure under SEBI regulations. Biocon emphasized its strong leadership team, headed by CEO & Managing Director Mr. Shreehas Tambe, and commitment to governance and performance.

Biocon Ltd clarified a news report suggesting Kiran Mazumdar-Shaw's succession, stating she remains the Executive Chairperson. The company confirmed there are no impending changes in executive management or ownership succession requiring disclosure under SEBI regulations. Biocon emphasized its strong leadership team, led by CEO & Managing Director Shreehas Tambe, and commitment to governance and performance, assuring that any material information will be disclosed as per regulations.

Biocon Ltd's Board of Directors will meet on May 7, 2026, to consider an investment in its unlisted material subsidiary, Biocon Biologics Limited (BBL). The investment will be through the purchase or acquisition of equity shares of BBL for consideration other than cash. This will involve the issuance and allotment of fully paid-up equity shares of Biocon on a preferential allotment basis through private placement. The company will seek shareholder approval via postal ballot.

Biocon Ltd announced that the U.S. Food and Drug Administration (FDA) completed a Pre-License Inspection (PLI) at its biosimilars manufacturing site in Biocon Park, Bengaluru, India. The inspection, conducted from April 20 to April 29, 2026, covered three Biologics Manufacturing units, five Quality testing laboratories, and two Warehouses. At its conclusion, the U.S. FDA issued a Form 483 with five observations. Biocon clarified that these observations are procedural in nature, do not relate to data integrity or quality oversight, and there were no repeat observations. The company is committed to submitting a comprehensive Corrective and Preventive Action (CAPA) plan within the stipulated timeline and is confident in addressing all observations expeditiously.

Biocon Ltd has announced that its Board of Directors will convene on Thursday, May 7, 2026. The primary agenda for this meeting is to approve and take on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Additionally, the Board will consider the recommendation of a dividend, if any. In compliance with insider trading regulations, the trading window for the company's securities has been closed from April 1, 2026, to May 9, 2026, and will reopen on May 10, 2026. The company will also host an Earnings Conference Call for analysts and investors on Friday, May 8, 2026, at 09:00 hrs IST to discuss the results.

Biocon Ltd has received Health Canada approval for Bosaya™ (denosumab), a biosimilar to Prolia®, and Vevzuo™ (denosumab), a biosimilar to Xgeva®, on April 3, 2026. This approval expands Biocon's access to high-quality biosimilars in key global markets. Bosaya™ is approved for treating osteoporosis in various patient groups, while Vevzuo™ targets skeletal-related events in patients with multiple myeloma and bone metastases from solid tumours, as well as giant cell tumour of bone. The approvals are based on comprehensive analytical, nonclinical, and clinical data, demonstrating high similarity to the reference products with no clinically meaningful differences in quality, safety, or efficacy. This strengthens Biocon's portfolio of affordable biologic therapies across immunology and oncology, potentially benefiting over 2 million adults with osteoporosis and hundreds of cancer patients annually.

Biocon Ltd has issued a reminder to shareholders holding shares in physical form to furnish their Know Your Customer (KYC) details. This action is in compliance with SEBI's Master Circular dated February 06, 2026, which mandates that payments like dividends will only be processed electronically once KYC details (PAN, contact, bank account, signature) are updated. Failure to update these details may result in dividend payments being withheld. Shareholders are advised to submit updated KYC information using Form ISR-1 and Form ISR-2, along with supporting documents, either physically or electronically to the company's Registrar and Share Transfer Agent, KFin Technologies Limited.